ReviewCritical care (London, England)2026
Dosing of anti-infective drugs in patients undergoing therapeutic plasma exchange - considerations for practical application: a narrative review.
Review in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic plasma exchange (TPE) is used in a wide range of indications and patient populations. The current guidelines of the American Society for Apheresis on the use of therapeutic apheresis in clinical practice list 166 graded indications for TPE. Many indications are related to the treatment of critically ill patients. Indeed, two multicenter trials are currently investigating the role of TPE in the treatment of early septic shock. MAIN BODY: During TPE, usually 1.0-1.5 times the calculated plasma volume is exchanged using albumin solution or fresh frozen plasma as replacement fluid, although considerable deviations from this recommended exchange volume have been reported. Depending on the TPE modality (membrane-based or centrifugal), the duration of the procedure ranges between 90 and 140 min. TPE removes not only unwanted substances such as inflammatory mediators or pathological antibodies but may also remove drugs that are essential for the treatment of the underlying disease. Furthermore, changes in plasma protein concentrations due to TPE may affect the volume of distribution (Vd) and the concentrations of protein-bound drugs. The objective of the current narrative review is to introduce general principles of TPE-associated drug removal as well as the current literature on the dosing of anti-infectives in patients undergoing TPE.
conclusionPharmacokinetic characteristics, including volume of distribution, plasma protein binding, endogenous clearance, and redistribution kinetics, have been demonstrated to influence the susceptibility of a drug to TPE-associated removal. TPE may substantially affect plasma levels of drugs with low volume of distribution and high protein binding, including aminoglycosides and glycopeptides. Further studies are needed because direct evidence on the pharmacokinetics of anti-infective drugs undergoing TPE in sepsis remains limited. Specific timing or dosing strategies are therefore not supported by sufficient evidence and should be individualized according to drug-specific pharmacokinetics, TPE characteristics, and clinical situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.